CompletedNot Applicable

Falls: A Marker of Preclinical AD

United States355 participantsStarted 2019-03-07

Plain-language summary

This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 65 years of age or older
✓. cognitively normal (Clinical Dementia Rating \[CDR\] score of 0)
✓. have biomarkers (CSF), and/or neuroimaging (positron emission tomography \[PET\] and/or magnetic resonance imaging \[MRI\]) within 2 years of enrolling in this study.

What they're measuring

Number and Severity of Falls

Timeframe: Cumulative falls at 4 years post-enrollment

Change from baseline: Dynamic balance and mobility

Timeframe: 4 years post-enrollment

Change from baseline: Gait Speed

Timeframe: 4 years post-enrollment

Change from baseline: Dual-task gait

Timeframe: 4 years post-enrollment

Trial details

NCT IDNCT04949529

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04-30

View on ClinicalTrials.gov More Fall trials